Tweet Group

Nov 18

Testing & Diagnosis
Pfizer and BioNTech Covid-19 vaccine is 95% effective, full results show
The companies said that they plan to submit to the Food and Drug Administration for an emergency use authorization “within days."
Eric Topol @EricTopol - Wed Nov 18
The @Pfizer/@BioNTech_Group vaccine trial is complete for efficacy. Of 43,661 participants, 170 events, 162 in placebo group, 8 in the vaccine. That's 95% efficacy; *phenomenal*; replicated @moderna_tx, ~ as good as it gets👇… @damiangarde @matthewherper
742 2336 Open Tweet
3 expert retweets
Expert replies & quotes
Carl T. Bergstrom @CT_Bergstrom - Wed Nov 18
Pfizer and BioNTech to submit Covid-19 vaccine data to FDA as full results show 95% efficacy. Exceptionally good news and a strong personal incentive to hunker down for just a bit longer, knowing this is just around the corner.…
56 251 Open Tweet
2 expert retweets
Expert replies & quotes
Helen Branswell @HelenBranswell - Wed Nov 18
Pfizer-BioNTech #Covid19 vaccine trial final data are out and they look great. So much good news here. We don’t know durability — how long Covid vaccines will last — but that is always true with a new vaccine. This is really hopeful news.…
231 815 Open Tweet
1 expert retweets
Expert replies & quotes
Matthew Herper @matthewherper - Wed Nov 18
Pfizer and BioNTech: **FULL results **95% efficacy **Submitting EUA **Efficacy against severe disease **Side effects include fatigue, headache…
88 252 Open Tweet
2 expert retweets
𝙀𝙡𝙞 𝙋𝙚𝙧𝙚𝙣𝙘𝙚𝙫𝙞𝙘𝙝 🤚 🧼😷 @eliowa - Wed Nov 18
“About 30% of U.S. volunteers in Pfizer’s trial are people of color, the company said. Roughly 45% of U.S. participants are between the ages of 56 and 85“…
6 26 Open Tweet
Maureen Miller, PhD @MMEPINYC - Wed Nov 18
Full @pfizer #covid19 vaccine results data shows 95% effectiveness in #Clinicaltrial of more than 43,000 participants. Awaiting peer review, but this looks mighty hopeful!